|
292 Companies |
|
371 Products |
|
371 Products |
|
177 Mechanisms of Action |
|
18 Trials |
|
3684 News |
|
| «12345678910111213...7778» |
- | everolimus / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus (clinicaltrials.gov) - Feb 22, 2018
P2, N=54, Active, not recruiting, Sponsor: European Institute of Oncology
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2018 | Trial primary completion date: Mar 2018 --> Feb 2018
- | everolimus / Generic mfg.
Trial primary completion date, IO biomarker: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus (clinicaltrials.gov) - Feb 19, 2018
P2, N=47, Recruiting, Sponsor: European Institute of Oncology
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2018 | Trial primary completion date: Mar 2018 --> Feb 2018 Trial primary completion date: Jun 2017 --> Mar 2018
- | Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Feb 13, 2018
P=N/A, N=23, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jun 2017 --> Mar 2018 Trial primary completion date: May 2017 --> May 2018 | Trial completion date: May 2017 --> May 2018
- | Trial completion date, Trial primary completion date: Prognostic Awareness and Patient-Physician Communication in Malignant Glioma (clinicaltrials.gov) - Feb 8, 2018
P=N/A, N=95, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: May 2017 --> May 2018 | Trial completion date: May 2017 --> May 2018 Trial primary completion date: Dec 2018 --> Dec 2019 | Trial completion date: Dec 2018 --> Dec 2019
- | Yervoy (ipilimumab) / BMS
Trial completion: Study of Ipilimumab in the Immune System (clinicaltrials.gov) - Feb 8, 2018
P=N/A, N=4, Completed, Sponsor: University Health Network, Toronto
Trial primary completion date: Dec 2018 --> Dec 2019 | Trial completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- | Trial completion: Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas (clinicaltrials.gov) - Feb 7, 2018
P1/2, N=22, Completed, Sponsor: Frank Lieberman
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | citicoline / Generic mfg.
Enrollment closed, Trial completion date, Trial initiation date, Trial primary completion date: Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy (clinicaltrials.gov) - Feb 7, 2018
P=N/A, N=80, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Initiation date: Dec 2011 --> Jun 2012 | Trial primary completion date: Dec 2018 --> Jun 2013 | Trial completion date: Dec 2018 --> Jun 2023
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial withdrawal: Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab (clinicaltrials.gov) - Feb 7, 2018
P2, N=0, Withdrawn, Sponsor: University of Utah
Recruiting --> Active, not recruiting | Initiation date: Dec 2011 --> Jun 2012 | Trial primary completion date: Dec 2018 --> Jun 2013 | Trial completion date: Dec 2018 --> Jun 2023 N=30 --> 0 | Not yet recruiting --> Withdrawn
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Feb 6, 2018
P2, N=40, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
N=30 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Oct 2010 --> Mar 2017
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Trial primary completion date, Combination therapy, PARP Biomarker, IO biomarker: CRUK-CR0901-11: Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma (clinicaltrials.gov) - Feb 5, 2018
P1, N=34, Completed, Sponsor: Cancer Research UK
Trial primary completion date: Oct 2010 --> Mar 2017 Recruiting --> Completed | Trial primary completion date: May 2017 --> Jun 2017
- ganetespib (ADX-1612) / Aldeyra
Trial primary completion date, Metastases: STA-9090(Ganetespib) in Metastatic Ocular Melanoma (clinicaltrials.gov) - Feb 1, 2018
P2, N=30, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed | Trial primary completion date: May 2017 --> Jun 2017 Trial primary completion date: Jun 2017 --> May 2016
- | Enrollment change, Trial termination, Trial primary completion date: MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients (clinicaltrials.gov) - Jan 31, 2018
P3, N=150, Terminated, Sponsor: European Institute of Oncology
Trial primary completion date: Jun 2017 --> May 2016 N=878 --> 150 | Recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Jul 2017; poor accrual rate
- | Biomarker, Trial completion, Enrollment change: Biomarkers for Prognosis of Glioblastoma (GBM) (clinicaltrials.gov) - Jan 31, 2018
P=N/A, N=19, Completed, Sponsor: University of Nebraska
N=878 --> 150 | Recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Jul 2017; poor accrual rate Active, not recruiting --> Completed | N=30 --> 19
- | doxazosin mesylate / Generic mfg.
Trial completion: PRESCRIPT: Phenoxybenzamine Versus Doxazosin in PCC Patients (clinicaltrials.gov) - Jan 31, 2018
P4, N=134, Completed, Sponsor: University Medical Center Groningen
Active, not recruiting --> Completed | N=30 --> 19 Recruiting --> Completed
- tasadenoturev (DNX-2401) / DNAtrix
Trial primary completion date: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Jan 31, 2018
P1b, N=37, Active, not recruiting, Sponsor: DNAtrix, Inc.
Recruiting --> Completed Trial primary completion date: Aug 2017 --> Mar 2018
- | temozolomide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma (clinicaltrials.gov) - Jan 29, 2018
P2, N=29, Completed, Sponsor: The Cleveland Clinic
Trial primary completion date: Aug 2017 --> Mar 2018 Active, not recruiting --> Completed | N=60 --> 29 | Trial primary completion date: Dec 2016 --> Jan 2008
- | SL-701 / Menarini
Trial completion: Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Jan 26, 2018
P1/2, N=74, Completed, Sponsor: Stemline Therapeutics, Inc.
Active, not recruiting --> Completed | N=60 --> 29 | Trial primary completion date: Dec 2016 --> Jan 2008 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies (clinicaltrials.gov) - Jan 24, 2018
P=N/A, N=56, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2018
- | Young TIL / National Cancer Institute
Trial completion, Metastases: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma (clinicaltrials.gov) - Jan 23, 2018
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2018 Active, not recruiting --> Completed
- ||||||| Taxoprexin (DHA-paclitaxel) / Daiichi Sankyo
Trial completion: Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma (clinicaltrials.gov) - Jan 23, 2018
P3, N=575, Completed, Sponsor: Luitpold Pharmaceuticals
Active, not recruiting --> Completed No longer recruiting --> Completed
- ADU-623 / Novartis
Trial primary completion date: Phase I Study of Safety and Immunogenicity of ADU-623 (clinicaltrials.gov) - Jan 18, 2018
P1, N=11, Active, not recruiting, Sponsor: Providence Health & Services
No longer recruiting --> Completed Trial primary completion date: Dec 2017 --> Jun 2018
- || agerafenib (RXDX-105) / Roche, Daiichi Sankyo
Trial primary completion date, Metastases: Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors (clinicaltrials.gov) - Jan 18, 2018
P1, N=143, Active, not recruiting, Sponsor: Ignyta, Inc.
Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | vatalanib (PTK787) / Novartis, Bayer
Trial completion, Trial primary completion date: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2018
P1, N=96, Completed, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers (clinicaltrials.gov) - Jan 15, 2018
P1/2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009 Active, not recruiting --> Completed
- | Trial completion: Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions (clinicaltrials.gov) - Jan 9, 2018
P1, N=17, Completed, Sponsor: John Kirkwood
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=10, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 5, 2018
P1, N=26, Active, not recruiting, Sponsor: Altor BioScience
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 26 | Trial primary completion date: Nov 2017 --> Aug 2017
- || Zelboraf (vemurafenib) / Roche
Trial primary completion date: Safety Study of PLX4032 in Patients With Solid Tumors (clinicaltrials.gov) - Dec 30, 2017
P1, N=75, Active, not recruiting, Sponsor: Plexxikon
Recruiting --> Active, not recruiting | N=20 --> 26 | Trial primary completion date: Nov 2017 --> Aug 2017 Trial primary completion date: Jun 2014 --> Aug 2015
- sonolisib (PX 866) / Pfizer
Enrollment change: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=24, Terminated, Sponsor: Oncothyreon Inc.
Trial primary completion date: Jun 2014 --> Aug 2015 N=146 --> 24
- veliparib (ABT-888) / AbbVie
Trial completion, PARP Biomarker: ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=24, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=146 --> 24 Active, not recruiting --> Completed
- | Tabrecta (capmatinib) / Incyte, Novartis, buparlisib (AN2025) / Adlai Nortye
Trial completion, Combination therapy: Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=42, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial termination, Metastases: Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (clinicaltrials.gov) - Dec 29, 2017
P2, N=10, Terminated, Sponsor: Melanoma Research Foundation Breakthrough Consortium
Active, not recruiting --> Completed N=162 --> 10 | Recruiting --> Terminated; Slow accrual; toxicity; change in priorities
- ||| buparlisib (AN2025) / Adlai Nortye
Trial initiation date, Trial primary completion date: Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma (clinicaltrials.gov) - Dec 29, 2017
P2, N=65, Active, not recruiting, Sponsor: Patrick Y. Wen, MD
N=162 --> 10 | Recruiting --> Terminated; Slow accrual; toxicity; change in priorities Initiation date: May 2011 --> Sep 2011 | Trial primary completion date: Aug 2015 --> Oct 2016
- | epacadostat (INCB024360) / Incyte
New P2 trial, IO biomarker, Metastases: Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - Dec 29, 2017
P2, N=12, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial primary completion date: A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 (clinicaltrials.gov) - Dec 29, 2017
P2, N=15, Completed, Sponsor: University Hospital Tuebingen
Initiation date: May 2011 --> Sep 2011 | Trial primary completion date: Aug 2015 --> Oct 2016 Recruiting --> Completed | N=41 --> 15 | Trial primary completion date: Feb 2014 --> Sep 2014
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Combination therapy, IO biomarker, Metastases: Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma (clinicaltrials.gov) - Dec 29, 2017
P1, N=8, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | N=41 --> 15 | Trial primary completion date: Feb 2014 --> Sep 2014 Active, not recruiting --> Completed
- ||||| Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) (clinicaltrials.gov) - Dec 29, 2017
P3, N=677, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, Metastases: Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma (clinicaltrials.gov) - Dec 29, 2017
P1/2, N=82, Completed, Sponsor: University Hospital Erlangen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date, Surgery: Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets (clinicaltrials.gov) - Dec 28, 2017
P2, N=2, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=39 --> 2 | Trial primary completion date: May 2015 --> Jan 2016
- ||||| Tafinlar (dabrafenib) / Novartis, BeiGene
Enrollment change, Metastases: A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma (clinicaltrials.gov) - Dec 28, 2017
P3, N=200, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=39 --> 2 | Trial primary completion date: May 2015 --> Jan 2016 N=250 --> 200
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion, Metastases: Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Dec 28, 2017
P2, N=21, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=250 --> 200 Terminated --> Completed
- || Lartruvo (olaratumab) / Eli Lilly, Cyramza (ramucirumab) / Eli Lilly
Trial primary completion date: Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Dec 27, 2017
P2, N=80, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Terminated --> Completed Trial primary completion date: Dec 2013 --> Jun 2012
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Trial primary completion date: AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Dec 27, 2017
P2, N=60, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2013 --> Jun 2012 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Jan 2016
- | dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
Trial termination, Trial primary completion date: ODSH + ICE Chemotherapy in Pediatric Solid Tumors (clinicaltrials.gov) - Dec 22, 2017
P1, N=4, Terminated, Sponsor: New York Medical College
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Jan 2016 Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2017; low accrual
- | humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion, Enrollment change, Trial primary completion date: A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas (clinicaltrials.gov) - Dec 22, 2017
P1, N=8, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2017; low accrual Recruiting --> Completed | N=36 --> 8 | Trial primary completion date: Sep 2020 --> Dec 2017
- |||||||||| Zelboraf (vemurafenib) / Roche
New P3 trial, Metastases: A Study of Vemurafenib in Participants With Metastatic Melanoma (clinicaltrials.gov) - Dec 19, 2017
P3, N=3219, Completed, Sponsor: Hoffmann-La Roche
- cyclophosphamide / Generic mfg.
Trial termination, Metastases: CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma (clinicaltrials.gov) - Dec 19, 2017
P2, N=10, Terminated, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Completed | N=36 --> 8 | Trial primary completion date: Sep 2020 --> Dec 2017 Completed --> Terminated; Primary Endpoint not met
- | dovitinib (TKI258) / Novartis, Oncoheroes
Trial completion, Trial primary completion date: Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma (clinicaltrials.gov) - Dec 19, 2017
P2, N=33, Completed, Sponsor: Manmeet Ahluwalia, MD
Completed --> Terminated; Primary Endpoint not met Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2015
- | alisertib (MLN8237) / Puma
Trial completion, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 19, 2017
P2, N=72, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2015 Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015
- | Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Surgery, Metastases: Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery (clinicaltrials.gov) - Dec 19, 2017
P2, N=13, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015 Active, not recruiting --> Completed